Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 6, 2020
Reporting Period: Immediate event reporting regarding material agreements entered into on February 6, 2020.
Collegium Pharmaceutical, Inc. announced the entry into a definitive Asset Purchase Agreement to acquire the NUCYNTA® franchise from Assertio Therapeutics, Inc. (f/k/a Depomed, Inc.). The company also secured term loan financing to fund a portion of this acquisition.
Key Financial Metrics and Transaction Terms
| Metric | Value/Detail |
|---|---|
| Total Purchase Price | $375,000,000 (subject to adjustments) |
| Term Loan Amount | $200,000,000 |
| Loan Interest Rate | LIBOR (2.0% floor) + 7.5% margin |
| Loan Maturity | 48 months from Closing |
| Repayment Structure | Equal quarterly principal payments starting 3 months post-closing |
| Post-Closing Royalty | 14% of net sales to Grünenthal GmbH (replaces previous structure) |
| Termination Fees | $7,500,000 (payable by Collegium if financing fails; receivable by Collegium if closing fails by outside date) |
Note: This filing does not provide current revenue, profit, cash flow, or margin data for the company.
Material Changes and Strategic Shifts
- Acquisition of Assets: Collegium is acquiring assets related to the NUCYNTA® franchise, transitioning from a commercialization rights model to full asset ownership.
- Termination of Prior Agreement: The existing Commercialization Agreement with Assertio will be terminated upon closing, ceasing Collegium's payment obligations to Assertio.
- Royalty Restructuring: Post-closing, Collegium will pay royalties directly to Grünenthal GmbH at 14% of net sales. The previous guaranteed royalty of $34 million (applicable when net sales were between $180 million and $243 million) is removed.
- Debt Incurrence: The company is taking on significant secured debt ($200 million) collateralized by substantially all company assets.
Guidance, Risks, and Covenants
Loan Covenants and Restrictions
The Term Loan Agreement imposes strict covenants, including:
- Sales Requirement: The company must maintain $200 million in annual net sales.
- Restrictions: Limits on incurring additional indebtedness, creating liens, making acquisitions, or disposing of assets outside the ordinary course of business.
- Default Consequences: Failure to comply constitutes an event of default, allowing lenders to accelerate repayment and execute on collateral.
Risks and Contingencies
- Closing Conditions: The transaction is contingent on satisfying closing conditions for both the Purchase Agreement and the Loan Agreement.
- Financing Risk: If the company fails to obtain financing, it must pay a $7.5 million termination fee to Assertio.
- Timeline Risk: If the closing does not occur by the "outside date" of March 13, 2020, due to unsatisfied conditions, the company is entitled to a $7.5 million termination fee from Assertio.
- Forward-Looking Statements: Management notes substantial risks and uncertainties regarding the ability to satisfy closing conditions and future performance.
Investor Verification Checklist
- Verify the final closing date and whether the $375 million purchase price was adjusted post-closing.
- Confirm the company's ability to meet the $200 million annual net sales covenant required by the new loan.
- Review the full text of the Purchase Agreement (Exhibit 10.1) and Loan Agreement (Exhibit 10.2) for specific indemnification limitations and representations.
- Monitor the company's liquidity position to ensure it can service the quarterly principal payments on the $200 million term loan.
- Assess the impact of removing the $34 million guaranteed royalty floor on future cash flow projections.